Kiora Pharmaceuticals Overview

  • Year Founded
  • 1998

Year Founded

  • Status
  • Public

  • Employees
  • 13

Employees

  • Stock Symbol
  • KPRX

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $0.82
  • (As of Wednesday Closing)

Kiora Pharmaceuticals General Information

Description

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Contact Information

Formerly Known As
Eyegate Pharmaceuticals, Optis France
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 169 Saxony Road
  • Suite 212
  • Encinitas, CA 92024
  • United States
+1 (781)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 169 Saxony Road
  • Suite 212
  • Encinitas, CA 92024
  • United States
+1 (781)

Kiora Pharmaceuticals Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kiora Pharmaceuticals Stock Performance

As of 18-Nov-2026, Kiora Pharmaceuticals’s stock price is $0.82. Its current market cap is $3.65M with 4.42M shares.

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.82 $0.93 $0.78 - $2.91 $3.65M 4.42M 34.2K -$2.68

Kiora Pharmaceuticals Financials Summary

As of 30-Sep-2026, Kiora Pharmaceuticals has a trailing 12-month revenue of $1M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV (5,179) (11,726) (19,060) (1,365)
Revenue 1,000 0 16,000 0
EBITDA (13,805) (12,967) 4,448 (12,531)
Net Income (12,763) (10,835) 3,595 (12,514)
Total Assets 22,374 24,253 36,484 13,712
Total Debt 287 368 57 107
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Kiora Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Kiora Pharmaceuticals‘s full profile, request access.

Request a free trial

Kiora Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Kiora Pharmaceuticals‘s full profile, request access.

Request a free trial

Kiora Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the trea
Drug Discovery
Encinitas, CA
13 As of 2025

Watertown, MA
 

Cambridge, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Kiora Pharmaceuticals Competitors (11)

One of Kiora Pharmaceuticals’s 11 competitors is EyePoint, a Corporation company based in Watertown, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
EyePoint Corporation Watertown, MA
Foventa Therapeutics Venture Capital-Backed Cambridge, United Kingdom
Limnopharma Venture Capital-Backed Granada, Spain
Opus Genetics Formerly VC-backed Durham, NC
Kodiak Sciences Formerly VC-backed Palo Alto, CA
You’re viewing 5 of 11 competitors. Get the full list »

Kiora Pharmaceuticals Patents

Kiora Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2023172818-A1 Polymorphs of a dihydroorotate dehydrogenase (dhod) inhibitor Inactive 09-Mar-2022
WO-2023168176-A1 Salts of a dihydroorotate dehydrogenase (dhod) inhibitor Inactive 01-Mar-2022
CA-3173160-A1 Compositions and methods for treating ocular disease by contact lens mediated drug delivery Pending 25-Mar-2020
EP-4125813-A1 Compositions and methods for treating ocular disease by contact lens mediated drug delivery Inactive 25-Mar-2020
US-20210299039-A1 Compositions and methods for treating ocular disease by contact lens mediated drug delivery Inactive 25-Mar-2020 A61K9/0051
To view Kiora Pharmaceuticals’s complete patent history, request access »

Kiora Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kiora Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Kiora Pharmaceuticals‘s full profile, request access.

Request a free trial

Kiora Pharmaceuticals Acquisitions (3)

Kiora Pharmaceuticals’s most recent deal was a Merger/Acquisition with Bayon Therapeutics for . The deal was made on 21-Oct-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Bayon Therapeutics 21-Oct-2021 Merger/Acquisition Drug Discovery
Panoptes Pharma 18-Dec-2020 Merger/Acquisition Drug Discovery
Jade Therapeutics 07-Mar-2016 Merger/Acquisition Pharmaceuticals
To view Kiora Pharmaceuticals’s complete acquisitions history, request access »

Kiora Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

35.43 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Kiora Pharmaceuticals’s complete esg history, request access »

Kiora Pharmaceuticals FAQs

  • When was Kiora Pharmaceuticals founded?

    Kiora Pharmaceuticals was founded in 1998.

  • Where is Kiora Pharmaceuticals headquartered?

    Kiora Pharmaceuticals is headquartered in Encinitas, CA.

  • What is the size of Kiora Pharmaceuticals?

    Kiora Pharmaceuticals has 13 total employees.

  • What industry is Kiora Pharmaceuticals in?

    Kiora Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Kiora Pharmaceuticals a private or public company?

    Kiora Pharmaceuticals is a Public company.

  • What is Kiora Pharmaceuticals’s stock symbol?

    The ticker symbol for Kiora Pharmaceuticals is KPRX.

  • What is the current stock price of Kiora Pharmaceuticals?

    As of 18-Nov-2026 the stock price of Kiora Pharmaceuticals is $0.82.

  • What is the current market cap of Kiora Pharmaceuticals?

    The current market capitalization of Kiora Pharmaceuticals is $3.65M.

  • What is Kiora Pharmaceuticals’s current revenue?

    The trailing twelve month revenue for Kiora Pharmaceuticals is $1M.

  • Who are Kiora Pharmaceuticals’s competitors?

    EyePoint, Foventa Therapeutics, Limnopharma, Opus Genetics, and Kodiak Sciences are some of the 11 competitors of Kiora Pharmaceuticals.

  • What is Kiora Pharmaceuticals’s annual earnings per share (EPS)?

    Kiora Pharmaceuticals’s EPS for 12 months was -$2.68.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process